Moderna said Monday that its COVID-19 vaccine is able to generate a strong immune response in children ages 6 to 11, citing a new study.
The company said that an interim analysis of data showed a “robust neutralizing antibody response” after two shots of its mRNA-1273 vaccine were administered at a 50 microgram dose level, or half the dosage of the vaccine used in adults, to children in this age group.
